.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX16_Plerixafor.Plerixafor .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX16_Plerixafor.Plerixafor| name: | Plerixafor |
| ATC code: | L03AX16 | route: | subcutaneous |
| n-compartments | 1 |
Plerixafor is a hematopoietic stem cell mobilizer that acts as a CXCR4 antagonist. It is used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Plerixafor is currently approved by regulatory agencies such as FDA and EMA for this indication.
Pharmacokinetic parameters in healthy volunteers and patients with multiple myeloma or non-Hodgkin’s lymphoma, adults of both sexes; after a single subcutaneous injection.
Cashen, A, et al., & DiPersio, J (2008). A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 14(11) 1253–1261. DOI:10.1016/j.bbmt.2008.08.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18940680
Lack, NA, et al., & Bridger, G (2005). A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clinical pharmacology and therapeutics 77(5) 427–436. DOI:10.1016/j.clpt.2004.12.268 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15900288